Tofacitinib citrate orally disintegrating tablet and preparation method thereof
By preparing the truncated slabs of citrate, using the mixing and processing technology of specific components, the existing truncated slabs of citrate and sustained release sheets have been solved, and the problem of slow disintegration and poor stability has been achieved, thus achieving rapid The onset and stability are improved, meeting the medication needs of juvenile idiopathic arthritis patients.
Patent Information
- Application Number
- CN202411013624.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-08
AI Technical Summary
The existing citrate trody cloth sheets and sustained-release tablets are difficult to control during use, the product has poor stability, slow disintegration rate, and cannot take effect quickly. It is only suitable for adult patients and cannot meet the idiopathicity of young people. The needs of patients with arthritis.
The preparation method of truncated tablets using tomato-propyl citrate includes truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated truncated trun The ingredients such as sodium fumarate are mixed in a specific proportion and are made by hot melt extrusion, cooling of whole pellets, wet granulation, drying and whole pellets, forming oral collapse sheets that are fast disintegrating and dissolution.
The rapid disintegration and dissolution of tofatifib citrate is achieved, which improves the onset speed and is suitable for patients of all ages. It does not require water orally to be taken directly, improves patient compliance and enhances product stability.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of tofacitinib citrate, and particularly relates to a tofacitinib citrate orally disintegrating tablet and a preparation method thereof. Background Art
[0002] Rheumatoid arthritis (RA) is a chronic autoimmune disease with a high clinical morbidity and disability rate. Its main pathological feature is chronic progressive synovitis, which can occur at any age. If standardized treatment is not given in time, the condition can gradually worsen, eventually leading to deformity, joint ankylosis and loss of function. It is one of the most common and major disabling diseases in clinical practice. Rheumatoid arthritis, RA can cause a variety of clinical symptoms, mainly manifested as polyarticular, symmetrical, invasive joint inflammation of the small joints of the hands and feet, often accompanied by extra-articular organ involvement and positive serum rheumatoid factor, leading to joint deformity and loss of function.
[0003] Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease of infants and adolescents. It is a highly variable disease with a global incidence of approximately 1.6-23.0 / 100,000. At present, there is a lack of children-specific drugs for the treatment of juvenile idiopathic arthritis (JIA), and the situation of this indication is severe.
[0004] Tofacitinib citrate is the first JAK pathway inhibitor with a specific mechanism of action and is a new type of oral protein tyrosine kinase inhibitor. Tofacitinib citrate tablets and tofacitinib citrate extended-release tablets were developed and marketed by Pfizer Inc. in the United States and were approved by the U.S. FDA in November 2012 and February 2016, respectively, for the treatment of moderate to severe adult RA patients who have an inadequate response or intolerance to methotrexate.
[0005] So far, Tofacitinib Citrate Tablets and Tofacitinib Citrate Sustained-Release Tablets are available in both domestic and overseas markets. However, during the use of the currently available Tofacitinib Citrate Tablets and Tofacitinib Citrate Sustained-Release Tablets, impurities are difficult to control and product stability is poor. The disintegration rate of both the regular tablets and the sustained-release tablets is slow, and the onset of action is slow, which cannot achieve a rapid onset of action. In addition, the above two preparations are only for adult patients and cannot meet the needs of patients with juvenile idiopathic arthritis.
[0006] Therefore, how to improve patient compliance, increase the speed of onset of action, and at the same time meet the medication needs of patients with juvenile idiopathic arthritis is the most serious problem currently facing this product. Summary of the invention
[0007] In order to solve the problems in the prior art, the present invention provides a tofacitinib citrate orally disintegrating tablet and a preparation method thereof, so as to improve patient compliance, increase the speed of onset of action, and meet the medication needs of patients with juvenile idiopathic arthritis.
[0008] The present invention solves the technical problem by adopting the following technical solutions:
[0009] The present invention aims to provide a tofacitinib citrate orally disintegrating tablet, which comprises, by weight, 10 to 20 parts of tofacitinib citrate, 30 to 35 parts of glucose, 0.05 to 0.08 parts of triethanolamine, 0.03 to 0.06 parts of polyvinyl alcohol, 50 to 55 parts of polyethylene glycol 3000, 20 to 23 parts of microcrystalline cellulose, 3.2 to 4.5 parts of sodium hydroxypropyl starch, 8 to 10 parts of lactose, and 0.6 to 0.8 parts of sodium stearyl fumarate.
[0010] Furthermore, in parts by weight, it includes 15 parts of tofacitinib citrate, 32 parts of glucose, 0.06 parts of triethanolamine, 0.04 parts of polyvinyl alcohol, 52 parts of polyethylene glycol 3000, 22 parts of microcrystalline cellulose, 3.9 parts of sodium hydroxypropyl starch, 9 parts of lactose, and 0.7 parts of sodium stearyl fumarate.
[0011] A method for preparing a tofacitinib citrate orally disintegrating tablet comprises the following steps:
[0012] S1. Raw material pretreatment: (1) taking the formulated amount of tofacitinib citrate, glucose, triethanolamine, polyvinyl alcohol, and polyethylene glycol 3000, respectively, placing them in a universal grinder, crushing them, sieving them, and mixing them to obtain a mixed powder for later use; (2) then hot-melt-extrude the mixed powder in step (1) to obtain a mixed strip; (3) after cooling the mixed strip, crushing and granulating it to obtain hot-melt-extruded particles for later use;
[0013] S2 premixing: Take the formulated amount of microcrystalline cellulose and lactose, mix them, add the hot melt extruded particles prepared in S1, continue mixing to obtain premixed particles, and set aside;
[0014] S3 granulation: take the premixed granules in S2, add ethanol solution, and wet granulate to obtain a soft material; granulate the prepared soft material to obtain wet granules;
[0015] S4 drying: drying the wet granules to obtain dry granules for later use;
[0016] S5 granulation: granulating the dried granules;
[0017] S6 total mixing: mix the formulated amount of sodium hydroxypropyl starch with the S5 whole granules, then add the formulated amount of sodium stearyl fumarate, and continue mixing to obtain the total mixed granules;
[0018] S7 tableting: tableting the total mixed granules in a mold to obtain tofacitinib citrate orally disintegrating tablets.
[0019] Furthermore, in S1, (1) taking the formula amount of tofacitinib citrate, glucose, triethanolamine, polyvinyl alcohol, and polyethylene glycol 3000, respectively, placing them in a universal grinder, crushing them, passing them through a 100-mesh sieve, and then taking the above sieved powders, placing them in a three-dimensional motion mixer, setting the speed to 20 to 30 rpm, mixing for 20 to 30 minutes, taking out the mixed powder, and setting it for use; (2) starting the hot melt extruder, setting the hot melt temperature to 130 to 150° C., setting the screw speed to 80 to 100 rpm, and then uniformly adding the mixed powder in step (1) to the hot melt extruder, collecting the output, and obtaining a mixed strip; (3) cooling the mixed strips to room temperature, controlling the relative humidity of the air to be less than 50%, and crushing and granulating the mixed strips using a high-speed crushing and granulating machine, the sieve aperture being 1.0 to 1.2 mm, and completing the granulation to obtain hot melt extruded particles.
[0020] Furthermore, the formulated amount of microcrystalline cellulose and lactose in S2 is placed in a three-dimensional motion mixer, the speed is set to 20 to 30 rpm, and mixed for 30 to 40 minutes. Then, the hot-melt extruded particles prepared in S1 are added to the three-dimensional motion mixer, and mixing is continued for 10 to 20 minutes to obtain premixed particles.
[0021] Furthermore, the premixed particles in S3 are taken and placed in a wet granulator, and an ethanol solution with a volume fraction of 70% to 90% is added, the mass ratio of the premixed particles to the ethanol solution with a volume fraction of 70% to 90% is 100:20 to 30, and after low-speed stirring for 2 to 5 minutes, the low-speed cutter is turned on for 30 to 60 seconds, and then the high-speed cutter is turned on for 20 to 30 seconds to obtain a soft material; the prepared soft material is passed through the discharge port of the high-efficiency wet granulator and loaded into a clean turnover barrel, and a swing granulator equipped with a 20-mesh screen is started, the speed is set to 57r / min-63r / min, and the soft material is added for granulation to obtain wet granules.
[0022] Furthermore, in S4, the wet granules are placed in a boiling dry granulator, the air inlet temperature is set to 70-80°C, the air inlet temperature is adjusted and controlled to 60-90°C, and the air inlet frequency is 30-50Hz, so that the granules are in a fluidized state and dried until the moisture content of the granules is less than 3%, thereby obtaining dry granules.
[0023] Furthermore, in S5, an oscillating granulator equipped with a 20-mesh screen is started, the rotation speed of the oscillating granulator is 57 r / min-63 r / min, and the dried granules are added for granulation.
[0024] Furthermore, in S6, the formulated amount of sodium hydroxypropyl starch is added to the multi-directional motion mixer, the mixer is started, the speed is 13 rpm ± 5%, and mixing is performed for 10 to 15 minutes, and then the formulated amount of sodium stearyl fumarate is added, and mixing is continued for 5 to 8 minutes to obtain the total mixed granules.
[0025] Compared with the prior art, the beneficial technical effects of the present invention are:
[0026] 1. The tofacitinib citrate orodisintegrating tablets of the present invention disintegrate quickly, dissolve quickly, and take effect quickly; at the same time, the product does not require water for administration, and can meet the medication needs of special patients (elderly people, children (infants, adolescents), mental patients, Alzheimer's patients, etc.).
[0027] 2. The preparation method of conventional orally disintegrating tablets, through mixing, granulation, and tableting, cannot achieve disintegration below 20s, and cannot achieve rapid dissolution. The reason is that the orally disintegrating tablets prepared in this way will undergo two processes, namely disintegration and dissolution, so the dissolution will be much slower. In the orally disintegrating tablets prepared by the present invention, tofacitinib, glucose, triethanolamine, polyvinyl alcohol, and polyethylene glycol 3000 are linked between molecules to form a dispersion. After encountering water, due to the good water solubility of glucose and polyethylene glycol 3000, water can be quickly absorbed in water, and the molecules in the dispersion quickly disintegrate and dissolve rapidly. After the product is prepared into orally disintegrating tablets, the onset time can be improved to a certain extent, and it is easy to take, no water is needed, and it can be directly taken orally, thereby improving the compliance of patients.
[0028] 3. Hydroxypropyl starch sodium in the present invention can accelerate disintegration, polyvinyl alcohol can increase dissolution, disintegration and dissolution are improved. In addition, in addition to the improvement of disintegration and dissolution, the impurities in the present invention are more stable during the stability placement process. The reason is the link between molecules. The relatively stable excipients such as glucose and polyethylene glycol run through the inside and outside of the tofacitinib molecule to form a protective package, which reduces the contact with external light and oxygen, thereby improving stability.
[0029] The above description is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention, it can be implemented according to the contents of the specification. In order to make the above contents of the present invention and its objectives, features and advantages more obvious and easy to understand, the specific implementation methods of the present invention are listed below. DETAILED DESCRIPTION
[0030] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary illustrations and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0031] In addition, unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or prepared by existing methods.
[0032] A formulation of tofacitinib citrate orodisintegrating tablets is as follows:
[0033]
[0034] A preparation method of tofacitinib citrate orally disintegrating tablets:
[0035] 1. Raw material pretreatment: (1) Take the formulated amount of tofacitinib citrate, glucose, triethanolamine, polyvinyl alcohol, and polyethylene glycol 3000, respectively, place them in a universal grinder, grind them, and pass them through a 100-mesh sieve. Then take the sieved powders and place them in a three-dimensional motion mixer, set the speed to 20 to 30 rpm, mix for 20 to 30 minutes, take out the mixed powder, and set it aside;
[0036] (2) starting the hot melt extruder, setting the hot melt temperature to 130-150° C., setting the screw speed to 80-100 rpm, and then uniformly adding the mixed powder in step (1) to the hot melt extruder, collecting the output, and obtaining a mixed strip; (3) cooling the mixed strip to room temperature, controlling the relative humidity of the air to be less than 50%, and crushing and granulating the mixed strip using a high-speed crushing and granulating machine, wherein the sieve aperture is 1.0-1.2 mm. After granulation is completed, hot melt extruded particles are obtained for standby use;
[0037] 2. Premixing: Place the formulated amount of microcrystalline cellulose (filler) and lactose (filler) in a three-dimensional motion mixer, set the speed to 20-30 rpm, mix for 30-40 minutes, then add the hot melt extruded particles prepared in step 1 to the three-dimensional motion mixer, continue mixing for 10-20 minutes to obtain premixed particles for later use;
[0038] 3. Granulation: take the premixed granules, place them in a wet granulator, add an ethanol solution with a volume fraction of 70% to 90%, stir at a low speed for 2 to 5 minutes, turn on the low-speed cutter for 30 to 60 seconds, and then turn on the high-speed cutter for 20 to 30 seconds to obtain a suitable soft material; put the prepared soft material into a clean turnover barrel through the discharge port of the high-efficiency wet granulator, start a swing granulator equipped with a 20-mesh screen, set the speed to 57r / min-63r / min, add the soft material for granulation, and obtain wet granules; the mass ratio of the premixed granules to the ethanol solution with a volume fraction of 70% to 90% is 100:20 to 30;
[0039] 4. Drying: Place the wet granules in a fluidized bed drying granulator, set the air inlet temperature to 70-80°C, adjust and control the air inlet temperature to 60-90°C, and the air inlet frequency to 30-50Hz, so that the granules are in a fluidized state, and dry until the moisture content of the granules is less than 3%, and obtain dry granules for standby use;
[0040] 5. Granulation: Start the swing granulator (speed: 57r / min-63r / min) equipped with a 20-mesh screen, add the dried granules for granulation;
[0041] 6. Add the formulated amount of sodium hydroxypropyl starch (disintegrant) into the multi-directional motion mixer, start the mixer (speed: 13 rpm ± 5%), mix for 10 to 15 minutes, then add the formulated amount of sodium stearyl fumarate, continue mixing for 5 to 8 minutes, and obtain the total mixed granules;
[0042] 7. Use a suitable mold to compress the tablets, and the tablet hardness is 1 to 2 kg to obtain the tofacitinib citrate orally disintegrating tablet product of the present invention.
[0043] Example 1
[0044] A preparation method of tofacitinib citrate orally disintegrating tablets:
[0045] 1. Raw material pretreatment: (1) Take 15 parts of tofacitinib citrate, 32 parts of glucose, 0.06 parts of triethanolamine, 0.04 parts of polyvinyl alcohol, and 52 parts of polyethylene glycol 3000, respectively, put them in a universal grinder, grind them, pass them through a 100-mesh sieve, then take the above sieved powders, put them in a three-dimensional motion mixer, set the speed to 25 rpm, mix them for 25 minutes, take out the mixed powder, and set it aside; (2) Turn on the hot melt extruder, set the hot melt temperature to 140°C, set the screw speed to 90 rpm, and then uniformly add the mixed powder in step (1) to the hot melt extruder, collect the output, and obtain a mixed strip; (3) Cool the mixed strip to room temperature, control the relative humidity of the air to 30%, and use a high-speed crushing and granulating machine to crush and granulate the mixed strips, the sieve aperture is 1.1 mm, and the granulation is completed to obtain hot melt extruded particles, which are set aside;
[0046] 2. Premixing: put 22 parts of microcrystalline cellulose and 9 parts of lactose into a three-dimensional motion mixer, set the speed to 25 rpm, mix for 35 minutes, then add the hot melt extruded particles prepared in step 1 into the three-dimensional motion mixer, continue mixing for 15 minutes, and obtain premixed particles for later use;
[0047] 3. Granulation: Take the premixed granules, place them in a wet granulator, add ethanol solution with a volume fraction of 80%, stir at a low speed for 3 minutes, turn on the low-speed cutter for 45 seconds, and then turn on the high-speed cutter for 25 seconds to obtain a soft material; put the prepared soft material into a clean turnover barrel through the discharge port of the high-efficiency wet granulator, start the swing granulator equipped with a 20-mesh screen, set the speed to 60r / min, add the soft material for granulation, and obtain wet granules; the mass ratio of the premixed granules to the ethanol solution with a volume fraction of 80% is 100:25;
[0048] 4. Drying: Place the wet granules in a fluidized bed drying granulator, set the air inlet temperature to 75°C, adjust and control the air inlet temperature to 75°C, and the air inlet frequency to 40Hz, so that the granules are in a fluidized state, and dry until the moisture content of the granules is 1%, and obtain dry granules for use;
[0049] 5. Granulation: Start the swing granulator (speed: 60r / min) equipped with a 20-mesh screen, add the dried granules for granulation;
[0050] 6. Add 3.9 parts of sodium hydroxypropyl starch into a multi-directional motion mixer, start the mixer at a speed of 13 rpm, mix for 12 minutes, then add 0.7 parts of sodium stearyl fumarate, and continue mixing for 6 minutes to obtain a total mixed granule;
[0051] 7. The mold is used for tableting, and the tableting hardness is 1 kg, thereby obtaining tofacitinib citrate orally disintegrating tablets.
[0052] Example 2
[0053] A preparation method of tofacitinib citrate orally disintegrating tablets:
[0054] 1. Raw material pretreatment: (1) Take 10 parts of tofacitinib citrate, 30 parts of glucose, 0.05 parts of triethanolamine, 0.06 parts of polyvinyl alcohol, and 55 parts of polyethylene glycol 3000, respectively, put them in a universal grinder, grind them, pass them through a 100-mesh sieve, then take the above sieved powders, put them in a three-dimensional motion mixer, set the speed to 20 rpm, mix them for 20 minutes, take out the mixed powder, and set it aside; (2) Turn on the hot melt extruder, set the hot melt temperature to 130° C., set the screw speed to 80 rpm, and then uniformly add the mixed powder in step (1) to the hot melt extruder, collect the output, and obtain a mixed strip; (3) Cool the mixed strip to room temperature, control the relative humidity of the air to 40%, and use a high-speed crushing and granulating machine to crush and granulate the mixed strips, the sieve aperture is 1.0 mm, and the granulation is completed to obtain hot melt extruded particles, which are set aside;
[0055] 2. Premixing: put 20 parts of microcrystalline cellulose and 8 parts of lactose into a three-dimensional motion mixer, set the speed to 20 rpm, mix for 30 minutes, then add the hot melt extruded particles prepared in step 1 into the three-dimensional motion mixer, continue mixing for 10 minutes, and obtain premixed particles for later use;
[0056] 3. Granulation: Take the premixed granules, place them in a wet granulator, add 70% ethanol solution by volume, stir at low speed for 2 minutes, turn on the low-speed cutter for 30 seconds, and then turn on the high-speed cutter for 20 seconds to obtain a soft material; put the prepared soft material into a clean turnover barrel through the discharge port of the high-efficiency wet granulator, start the swing granulator equipped with a 20-mesh screen, set the speed to 57r / min, add the soft material for granulation, and obtain wet granules; the mass ratio of the premixed granules to the 80% ethanol solution by volume is 100:20;
[0057] 4. Drying: Place the wet granules in a fluidized bed drying granulator, set the air inlet temperature to 70°C, adjust and control the air inlet temperature to 60°C, and the air inlet frequency to 30Hz, so that the granules are in a fluidized state, and dry until the moisture content of the granules is 2%, and obtain dry granules for use;
[0058] 5. Granulation: Start the swing granulator (speed: 57r / min) equipped with a 20-mesh screen, add the dried granules for granulation;
[0059] 6. Add 3.2 parts of sodium hydroxypropyl starch into a multi-directional motion mixer, start the mixer at a speed of 13 rpm, mix for 10 minutes, then add 0.6 parts of sodium stearyl fumarate, and continue mixing for 5 minutes to obtain a total mixed granule;
[0060] 7. The mold is used for tableting, and the tableting hardness is 2 kg, thereby obtaining tofacitinib citrate orally disintegrating tablets.
[0061] Example 3
[0062] A preparation method of tofacitinib citrate orally disintegrating tablets:
[0063] 1. Raw material pretreatment: (1) Take 20 parts of tofacitinib citrate, 35 parts of glucose, 0.08 parts of triethanolamine, 0.03 parts of polyvinyl alcohol, and 50 parts of polyethylene glycol 3000, respectively, put them in a universal grinder, grind them, pass them through a 100-mesh sieve, then take the above sieved powders, put them in a three-dimensional motion mixer, set the speed to 30 rpm, mix them for 30 minutes, take out the mixed powder, and set it aside; (2) Turn on the hot melt extruder, set the hot melt temperature to 150° C., set the screw speed to 100 rpm, then add the mixed powder in step (1) to the hot melt extruder at a uniform speed, collect the output, and obtain a mixed strip; (3) Cool the mixed strip to room temperature, control the relative humidity of the air to 20%, and use a high-speed crushing and granulating machine to crush and granulate the mixed strips, the sieve aperture is 1.2 mm, and the granulation is completed to obtain hot melt extruded particles, which are set aside;
[0064] 2. Premixing: 23 parts of microcrystalline cellulose and 10 parts of lactose were placed in a three-dimensional motion mixer, the speed was set to 30 rpm, and the mixture was mixed for 40 minutes. Then, the hot melt extruded particles prepared in step 1 were added to the three-dimensional motion mixer, and the mixture was mixed for 20 minutes to obtain premixed particles for later use.
[0065] 3. Granulation: Take the premixed granules, place them in a wet granulator, add 90% ethanol solution by volume, stir at low speed for 5 minutes, turn on the low-speed cutter for 60 seconds, and then turn on the high-speed cutter for 30 seconds to obtain a soft material; put the prepared soft material into a clean turnover barrel through the discharge port of the high-efficiency wet granulator, start the swing granulator equipped with a 20-mesh screen, set the speed to 63r / min, add the soft material for granulation, and obtain wet granules; the mass ratio of the premixed granules to the 90% ethanol solution by volume is 100:30;
[0066] 4. Drying: Place the wet granules in a fluidized bed drying granulator, set the air inlet temperature to 80°C, adjust and control the air inlet temperature to 90°C, and the air inlet frequency to 50Hz, so that the granules are in a fluidized state, and dry until the moisture content of the granules is 1%, and obtain dry granules for use;
[0067] 5. Granulation: Start the swing granulator (speed: 63r / min) equipped with a 20-mesh screen, add the dried granules for granulation;
[0068] 6. Add 4.5 parts of sodium hydroxypropyl starch into a multi-directional motion mixer, start the mixer at a speed of 13 rpm, mix for 15 minutes, then add 0.8 parts of sodium stearyl fumarate, and continue mixing for 8 minutes to obtain a total mixed granule;
[0069] 7. The mold is used for tableting, and the tableting hardness is 1 kg, thereby obtaining tofacitinib citrate orally disintegrating tablets.
[0070] Comparative Example 1
[0071] A preparation method of tofacitinib citrate orally disintegrating tablets:
[0072] 1. Raw material pretreatment: (1) Take 15 parts of tofacitinib citrate and place it in a universal grinder, grind it, and pass it through a 100-mesh sieve twice;
[0073] 2. Premixing: Premix (1) Take 10 parts of sucralose and 9 parts of silicon dioxide, mix them, pass through a 160-mesh sieve for dispersion, and obtain premix powder 1 for use. Premix (2) Take 22 parts of microcrystalline cellulose; add microcrystalline cellulose, tofacitinib citrate, and premix powder 1 into a three-dimensional motion mixer, set the frequency to 40 Hz, and mix for 2 minutes. After mixing, obtain premix powder 2. Pass premix powder 2 through a 60-mesh sieve and sieve for dispersion. Premix (3) Put the sieved premix powder 2 into a three-dimensional motion mixer, set the frequency to 40 Hz, and mix for 2 minutes. After mixing, obtain premix powder 3. Pass premix powder 3 through a 60-mesh sieve and sieve for dispersion. Premix (4) Take 6 parts of mannitol and 3 parts of cross-linked polyvinylpyrrolidone; add the sieved premix powder 3, mannitol, and cross-linked polyvinylpyrrolidone into a three-dimensional motion mixer, set the frequency to 40 Hz, and mix for 5 minutes. After the mixing is completed, the premixed powder 4 is obtained. The premixed powder 4 is passed through a 40-mesh sieve for dispersion. Premixing (5) The premixed powder 4 after sieving is put into the three-dimensional mixer again, the frequency is set to 40 Hz, and the mixing is carried out for 15 minutes. After the premixing is completed, the premixed product is obtained.
[0074] 3. Total mixing: Take 5 parts of magnesium stearate; put the magnesium stearate into a three-dimensional mixer filled with premixed products, set the frequency to 40 Hz, and mix for 3 minutes. After mixing, the total mixed granules are obtained.
[0075] 4. The mold is used for tableting, and the tableting hardness is 1 kg, thereby obtaining tofacitinib citrate orally disintegrating tablets.
[0076] Comparative Example 2
[0077] A preparation method of tofacitinib citrate orally disintegrating tablets:
[0078] 1. Raw material pretreatment: add 15 parts of tofacitinib citrate, 32 parts of glucose, 0.06 parts of triethanolamine, 0.04 parts of polyvinyl alcohol, and 52 parts of polyethylene glycol 3000 to purified water under stirring, and perform ultrasonic treatment for 8 minutes to fully disperse the drug in the water; then use a high-speed disperser to shear at a speed of 10000 rpm for 8 minutes to obtain a suspension; and then cycle the high-pressure homogenizer at a pressure of 1500 bar for 4 times;
[0079] 2. Premixing: Place 22 parts of microcrystalline cellulose and 9 parts of lactose in a three-dimensional motion mixer, set the speed to 25 rpm, and mix for 35 minutes. Then, add the mixture obtained in step 1 to the three-dimensional motion mixer and continue mixing for 15 minutes to obtain a premixed material for later use.
[0080] 3. Granulation: Place the mixed material in a fluidized bed, preheat for 5 minutes, pump the wetting agent solution into the fluidized bed spray gun through a peristaltic pump, the spray gun atomization pressure is 0.2Mpa, and the granulation temperature is 50°C;
[0081] 4. Total mixing: Mix the obtained granules with 3.9 parts of sodium hydroxypropyl starch and 0.7 parts of sodium stearyl fumarate for 6 minutes to obtain total mixed granules;
[0082] 5. The mold is used for tableting, and the tableting hardness is 1 kg, thereby obtaining tofacitinib citrate orally disintegrating tablets.
[0083] Comparative Example 3
[0084] A preparation method of tofacitinib citrate orally disintegrating tablets:
[0085] 1. Raw material pretreatment: (1) Take 22 parts of tofacitinib citrate, 27 parts of glucose, 0.04 parts of triethanolamine, 0.01 parts of polyvinyl alcohol, and 57 parts of polyethylene glycol 3000, respectively, put them in a universal grinder, grind them, pass them through a 100-mesh sieve, then take the above sieved powders, put them in a three-dimensional motion mixer, set the speed to 25 rpm, mix them for 25 minutes, take out the mixed powder, and set it aside; (2) Turn on the hot melt extruder, set the hot melt temperature to 140°C, set the screw speed to 90 rpm, and then uniformly add the mixed powder in step (1) to the hot melt extruder, collect the output, and obtain a mixed strip; (3) Cool the mixed strip to room temperature, control the relative humidity of the air to 30%, and use a high-speed crushing and granulating machine to crush and granulate the mixed strips, the sieve aperture is 1.1 mm, and the granulation is completed to obtain hot melt extruded particles, which are set aside;
[0086] 2. Premixing: put 25 parts of microcrystalline cellulose and 6 parts of lactose into a three-dimensional motion mixer, set the speed to 25 rpm, mix for 35 minutes, then add the hot melt extruded particles prepared in step 1 into the three-dimensional motion mixer, continue mixing for 15 minutes, and obtain premixed particles for later use;
[0087] 3. Granulation: Take the premixed granules, place them in a wet granulator, add ethanol solution with a volume fraction of 80%, stir at a low speed for 3 minutes, turn on the low-speed cutter for 45 seconds, and then turn on the high-speed cutter for 25 seconds to obtain a soft material; put the prepared soft material into a clean turnover barrel through the discharge port of the high-efficiency wet granulator, start the swing granulator equipped with a 20-mesh screen, set the speed to 60r / min, add the soft material for granulation, and obtain wet granules; the mass ratio of the premixed granules to the ethanol solution with a volume fraction of 80% is 100:25;
[0088] 4. Drying: Place the wet granules in a fluidized bed drying granulator, set the air inlet temperature to 75°C, adjust and control the air inlet temperature to 75°C, and the air inlet frequency to 40Hz, so that the granules are in a fluidized state, and dry until the moisture content of the granules is 1%, and obtain dry granules for use;
[0089] 5. Granulation: Start the swing granulator (speed: 60r / min) equipped with a 20-mesh screen, add the dried granules for granulation;
[0090] 6. Add 3.0 parts of sodium hydroxypropyl starch into a multi-directional motion mixer, start the mixer at a speed of 13 rpm, mix for 12 minutes, then add 0.4 parts of sodium stearyl fumarate, and continue mixing for 6 minutes to obtain a total mixed granule;
[0091] 7. The mold is used for tableting, and the tableting hardness is 1 kg, thereby obtaining tofacitinib citrate orally disintegrating tablets.
[0092] The tofacitinib citrate orally disintegrating tablets prepared in Examples 1-3 and Comparative Examples 1-3 were subjected to performance tests, and the results are shown in the following table:
[0093]
[0094] Test Example 1: Dissolution Analysis Experiment
[0095] The specific method of dissolution analysis is as follows:
[0096] Inspection method: HPLC method (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0512)
[0097] Instruments: HPLC, dissolution apparatus, pH meter, electronic balance
[0098] Chromatographic column: Hypersil BDS-C18 (125×4mm, 5μm) or other column with equivalent performance
[0099] Detector: UV detector
[0100] Detection wavelength: 220nm
[0101] Column temperature: 30°C
[0102] Flow rate: 1.0ml / min
[0103] Injection volume: 20 μl
[0104] Mobile phase: A:B=80:20;
[0105] Mobile phase A: 0.01 mol / L potassium dihydrogen phosphate solution (adjusted to pH 6.3 with phosphoric acid)-acetonitrile (90:10);
[0106] Mobile phase B: acetonitrile-water (90:10).
[0107] The four media used in the dissolution experiment were 0.1 mol / L hydrochloric acid solution, pH 4.5 acetate buffer, pH 6.8 phosphate buffer and water, and the sampling time points were set at 5, 10, 15, 30 and 45 minutes.
[0108] Preparation of dissolution medium:
[0109] 0.1mol / L hydrochloric acid solution: measure 54ml of hydrochloric acid, dilute it to 6000ml with water, stir evenly, filter and obtain.
[0110] pH 4.5 acetate buffer: Take 17.94 g of sodium acetate trihydrate, add 9.6 ml of glacial acetic acid, add 6000 ml of purified water to dissolve, adjust the pH value to 4.5 with glacial acetic acid, stir evenly, filter and obtain.
[0111] pH 6.8 phosphate buffer: Take 40.84g of potassium dihydrogen phosphate and 5.38g of sodium hydroxide, add water to dissolve and dilute to 6000ml; adjust the pH value to 6.8 with 0.2mol / L sodium hydroxide solution or phosphoric acid, stir evenly, filter and obtain.
[0112] Aqueous solution: Measure 900 ml of purified water and use directly.
[0113] The dissolution method (Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0931 Method 2) uses 0.1 mol / L hydrochloric acid solution, pH 4.5 acetate buffer, pH 6.8 phosphate buffer, and 900 ml of aqueous solution as dissolution media, respectively, and the temperature is 37.0°C ± 0.5°C. The speed is 50 revolutions per minute, and the operation is carried out according to the law, and samples are taken after 5, 10, 15, 30, and 45 minutes.
[0114] Test solution: Take the sample prepared in Example 1, 900 ml of dissolution medium, and rotate at 50 revolutions per minute, and operate according to the law. At the specified time point, take 20 ml of the solution, filter, discard 5 ml of the initial filtrate, and take the subsequent filtrate.
[0115] Take the subsequent filtrate of the above-mentioned medium dissolution solution as the test solution.
[0116] Reference solution: Accurately weigh 5 mg of tofacitinib citrate reference substance, place in a 20 ml volumetric flask, add 50% methanol (methanol-water (50:50)) to about 60% of the volume of the volumetric flask, sonicate to dissolve, cool, dilute to the scale with 50% methanol, shake well, and make a solution containing approximately 0.25 mg of tofacitinib citrate per 1 ml.
[0117] Determination method: Take 20 μl of the test solution and the reference solution respectively, inject them into the chromatograph, record the chromatogram, and calculate the dissolution amount of each tablet.
[0118] Result determination: 85% of the labeled amount should comply with regulations.
[0119] The dissolution data of the samples prepared in Example 1 are shown in the following table:
[0120]
[0121]
[0122] Test Example 2: Long-term stability test
[0123] The samples prepared in Example 1 were subjected to a long-term stability test.
[0124] Test method: Refer to the stability test of Part II of the 2020 edition of the Chinese Pharmacopoeia
[0125] Test conditions: Long-term test temperature: 25±2℃
[0126] Long-term test humidity: RH60%±10%
[0127] Long-term test duration: 0, 3, 6, 9, 12, 18, 24, 36 months
[0128] Test results: Long-term test stability data is shown in the following table:
[0129]
[0130] The serial numbers of the above embodiments of the present invention are only for description and do not represent the advantages or disadvantages of the embodiments.
[0131] The embodiments of the present invention are described above, but the present invention is not limited to the above-mentioned specific implementation modes. The above-mentioned specific implementation modes are merely illustrative and not restrictive. Under the guidance of the present invention, ordinary technicians in this field can also make many forms without departing from the scope of protection of the purpose of the present invention and the claims, which are all within the protection of the present invention.
Claims
1. A tofacitinib citrate orally disintegrating tablet, characterized in that: In parts by weight, it includes 10 to 20 parts of tofacitinib citrate, 30 to 35 parts of glucose, 0.05 to 0.08 parts of triethanolamine, 0.03 to 0.06 parts of polyvinyl alcohol, 50 to 55 parts of polyethylene glycol 3000, 20 to 23 parts of microcrystalline cellulose, 3.2 to 4.5 parts of sodium hydroxypropyl starch, 8 to 10 parts of lactose, and 0.6 to 0.8 parts of sodium stearyl fumarate.
2. The tofacitinib citrate orally disintegrating tablet according to claim 1, characterized in that: In parts by weight, it includes 15 parts of tofacitinib citrate, 32 parts of glucose, 0.06 parts of triethanolamine, 0.04 parts of polyvinyl alcohol, 52 parts of polyethylene glycol 3000, 22 parts of microcrystalline cellulose, 3.9 parts of sodium hydroxypropyl starch, 9 parts of lactose, and 0.7 parts of sodium stearyl fumarate.
3. A method for preparing a tofacitinib citrate orally disintegrating tablet according to claim 1 or 2, characterized in that: The following steps are involved: S1. Raw material pretreatment: (1) taking tofacitinib citrate, glucose, triethanolamine, polyvinyl alcohol, and polyethylene glycol 3000, respectively, placing them in a universal grinder, crushing them, sieving them, and mixing them to obtain a mixed powder for later use; (2) then hot-melt-extrude the mixed powder in step (1) to obtain a mixed strip; (3) after cooling the mixed strip, crushing and granulating it to obtain hot-melt-extruded particles for later use; S2 premixing: mix microcrystalline cellulose and lactose, add the hot melt extruded particles prepared in S1, continue mixing to obtain premixed particles for later use; S3 granulation: take the premixed granules in S2, add ethanol solution, and wet granulate to obtain a soft material; granulate the prepared soft material to obtain wet granules; S4 drying: drying the wet granules to obtain dry granules for later use; S5 granulation: granulating the dried granules; S6 total mixing: mix sodium hydroxypropyl starch with S5 whole granules, then add the formulated amount of sodium stearyl fumarate, and continue mixing to obtain total mixed granules; S7 tableting: tableting the total mixed granules in a mold to obtain tofacitinib citrate orally disintegrating tablets.
4. A method for preparing a tofacitinib citrate orally disintegrating tablet according to claim 3, characterized in that: In S1, (1) taking the formula amount of tofacitinib citrate, glucose, triethanolamine, polyvinyl alcohol, and polyethylene glycol 3000, respectively, placing them in a universal grinder, crushing them, and passing them through a 100-mesh sieve, then taking the above sieved powders, placing them in a three-dimensional motion mixer, setting the speed to 20 to 30 rpm, mixing for 20 to 30 minutes, taking out the mixed powder, and setting it for use; (2) starting the hot melt extruder, setting the hot melt temperature to 130 to 150° C., setting the screw speed to 80 to 100 rpm, and then uniformly adding the mixed powder in step (1) to the hot melt extruder, collecting the output, and obtaining a mixed strip; (3) cooling the mixed strips to room temperature, controlling the relative humidity of the air to be less than 50%, and crushing and granulating the mixed strips using a high-speed crushing and granulating machine, the sieve aperture being 1.0 to 1.2 mm, and completing the granulation to obtain hot melt extruded particles.
5. The method for preparing a tofacitinib citrate orally disintegrating tablet according to claim 3, characterized in that: Take the formulated amount of microcrystalline cellulose and lactose in S2 and put them in a three-dimensional motion mixer, set the speed to 20-30 rpm, mix for 30-40 minutes, then add the hot-melt extruded particles prepared in S1 to the three-dimensional motion mixer, continue mixing for 10-20 minutes, and obtain premixed particles.
6. A method for preparing a tofacitinib citrate orally disintegrating tablet according to claim 3, characterized in that: The premixed particles in S3 are taken and placed in a wet granulator, and an ethanol solution with a volume fraction of 70% to 90% is added, the mass ratio of the premixed particles to the ethanol solution with a volume fraction of 70% to 90% is 100:20 to 30, and after low-speed stirring for 2 to 5 minutes, the low-speed cutter is turned on for 30 to 60 seconds, and then the high-speed cutter is turned on for 20 to 30 seconds to obtain a soft material; the prepared soft material is passed through the discharge port of the high-efficiency wet granulator and loaded into a clean turnover barrel, and a swing granulator equipped with a 20-mesh screen is started, the speed is set to 57r / min-63r / min, and the soft material is added for granulation to obtain wet particles.
7. A method for preparing a tofacitinib citrate orally disintegrating tablet according to claim 3, characterized in that: In S4, the wet granules are placed in a fluidized bed drying granulator, the air inlet temperature is set at 70-80°C, the air inlet temperature is adjusted and controlled at 60-90°C, and the air inlet frequency is 30-50Hz, so that the granules are in a fluidized state and dried until the moisture content of the granules is less than 3%, thereby obtaining dry granules.
8. The method for preparing a tofacitinib citrate orally disintegrating tablet according to claim 3, characterized in that: In S5, a swing granulator equipped with a 20-mesh screen is started at a rotation speed of 57 r / min-63 r / min, and the dried granules are added for granulation.
9. The method for preparing a tofacitinib citrate orally disintegrating tablet according to claim 3, characterized in that: In S6, the formulated amount of sodium hydroxypropyl starch is added to the multi-directional motion mixer, the mixer is started, the speed is 13 rpm ± 5%, and the mixture is mixed for 10 to 15 minutes, and then the formulated amount of sodium stearyl fumarate is added, and the mixture is continued to be mixed for 5 to 8 minutes to obtain the total mixed granules.
